Universal Biosensors Inc - Asset Resilience Ratio
Universal Biosensors Inc (UBI) has an Asset Resilience Ratio of 14.72% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read UBI liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2024)
This chart shows how Universal Biosensors Inc's Asset Resilience Ratio has changed over time. See UBI book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Universal Biosensors Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Universal Biosensors Inc (UBI) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$2.20 Million | 14.72% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$2.20 Million | 14.72% |
Asset Resilience Insights
- Moderate Liquidity: Universal Biosensors Inc has 14.72% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Universal Biosensors Inc Industry Peers by Asset Resilience Ratio
Compare Universal Biosensors Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Vitrolife AB
ST:VITR |
Medical Devices | 7.27% |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033 |
Medical Devices | 19.31% |
|
Tellgen Corp
SHE:300642 |
Medical Devices | 8.60% |
|
Lumos Diagnostics Holdings Ltd
AU:LDX |
Medical Devices | 9.40% |
|
T&R Biofab Co. Ltd
KQ:246710 |
Medical Devices | 0.12% |
|
Ok Biotech Co Ltd
TW:4155 |
Medical Devices | 0.32% |
|
Promimic AB
ST:PRO |
Medical Devices | 8.62% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
Annual Asset Resilience Ratio for Universal Biosensors Inc (2007–2024)
The table below shows the annual Asset Resilience Ratio data for Universal Biosensors Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 33.06% | AU$8.54 Million ≈ $6.05 Million |
AU$25.84 Million ≈ $18.28 Million |
-1.22pp |
| 2023-12-31 | 34.28% | AU$10.28 Million ≈ $7.27 Million |
AU$29.97 Million ≈ $21.21 Million |
-22.01pp |
| 2022-12-31 | 56.30% | AU$25.98 Million ≈ $18.38 Million |
AU$46.15 Million ≈ $32.65 Million |
+21.87pp |
| 2021-12-31 | 34.42% | AU$15.32 Million ≈ $10.84 Million |
AU$44.50 Million ≈ $31.49 Million |
-7.37pp |
| 2020-12-31 | 41.79% | AU$23.56 Million ≈ $16.67 Million |
AU$56.38 Million ≈ $39.89 Million |
-6.45pp |
| 2019-12-31 | 48.24% | AU$30.23 Million ≈ $21.39 Million |
AU$62.66 Million ≈ $44.34 Million |
+31.39pp |
| 2018-12-31 | 16.86% | AU$11.80 Million ≈ $8.35 Million |
AU$69.98 Million ≈ $49.51 Million |
-39.94pp |
| 2017-12-31 | 56.80% | AU$26.27 Million ≈ $18.59 Million |
AU$46.26 Million ≈ $32.73 Million |
+15.98pp |
| 2016-12-31 | 40.81% | AU$20.40 Million ≈ $14.44 Million |
AU$49.99 Million ≈ $35.37 Million |
+40.63pp |
| 2011-12-31 | 0.18% | AU$83.34K ≈ $58.97K |
AU$45.22 Million ≈ $31.99 Million |
-4.73pp |
| 2007-12-31 | 4.92% | AU$3.14 Million ≈ $2.22 Million |
AU$63.86 Million ≈ $45.18 Million |
-- |
About Universal Biosensors Inc
Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of… Read more